Ludwig-Maximilians-Universität München

Motility inhibitors as novel therapeutic approach against common intestinal pathogens

Helicobacter pylori, Campylobacter jejuni, and Campylobacter coli are among the most widespread bacterial pathogens and responsible for annually hundreds of thousands of cases of diarrhoea, intestinal inflammation, gastric ulcers and stomach cancer worldwide. The research group led by Christine ...

University Hospital Tübingen

New strategies for specific eradication of Staphylococcus aureus

In this project, the scientists develop genetically engineered phage lysins and specific bacteriocins for the elimination of hospital germs such as Staphylococcus aureus, they clarify mechanisms of potential resistance mechanisms, and they analyse whether broad-spectrum or specifically acting agents ...

Bernhard Nocht Institute for Tropical Medicine

Novel approaches for the management of chronic forms of schistosomiasis: the identification of adapted tools through the Madagascan example - NAMASTE

More than 230 million people are infected and 600 million are at risk of infection with schistosomiasis, which ranks top in terms of disability-adjusted life years (3.3 million DALYs) among neglected tropical diseases. Over 90 percent of those requiring treatment for schistosomiasis live in Africa ...

Heidelberg University Hospital

Nucleoside Booster Project: Broad-spectrum antivirals for pandemic preparedness

The SARS-CoV-2 pandemic and other epidemics in recent decades have highlighted the need to develop effective measures to combat emerging infectious diseases in a timely manner. For most emerging viral pathogens, no vaccines or antiviral drugs are yet available. Since it is difficult to predict which ...

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

Optimization of chlorotonils towards an orally available treatment

This project prepares the preclinical development of the semi-synthetic chlorotonil derivative dehalogenil for the treatment of bacterial infections caused by Gram-positive pathogens. Dehalogenil impresses with its potent and very rapid antibacterial effect, which is triggered by membrane ...

University Hospital Bonn

PAACT—Precision access to antibiotic compounds and targets

The PAACT project (short for: Precision Access to Antibiotic Compounds and Targets) serves as a hub within the DZIF for the discovery and characterisation of new antibacterial agents and lead structures. In the context of the project, the development pipeline of antibiotic candidates is continuously ...

University of Tübingen

PAFAP—Pseudomonas aeruginosa-focused anti-infectives pipeline

In the current WHO list of bacterial priority pathogens (WHO BPPL 2024), the World Health Organisation classifies carbapenem-resistant Pseudomonas aeruginosa bacteria as a high-priority pathogen, which means there is an urgent need for new anti-infectives to combat this problematic bacterium. To ...

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

Preclinical development of Amidochelocardins

The challenge of antibiotic drug development today is the discovery and optimisation of novel bioactive compounds that do not show cross-resistances with clinically applied antibiotics, ideally due to a novel mode of action (MoA) which adresses unexploited microbial targets. In the case of ...

University of Cologne

R-Net: Core network for the study of multidrug-resistant bacterial organisms

Implementation of evidence-based infection control practices to reduce healthcare-associated infection remains a national and international priority. R-Net investigates the effect of various interventions aimed at limiting the spread of infections due to multi-drug resistant organisms (MDRO) ...